Archives
Targeted Promoters and High-Yield Rabbit Pharming
2026-11-06
A literature-focused analysis of a 2025 study that used targeted insertion at the rabbit CSN2 locus to drive tdTomato expression in milk. The reported 15–20 g/L concentration in two homozygous females is striking, but the evidence remains a proof of concept because it concerns a reporter protein, a small animal cohort, and historical rather than contemporaneous comparisons.
How CSN2 Targeting Raised Rabbit Milk Yield
2026-11-05
A 2025 study examined whether placing a reporter gene at the endogenous rabbit CSN2 milk-protein locus could overcome the variable expression associated with conventional transgenic pharming. The reported 15–20 g/L tdTomato yield in two homozygous animals is substantial, but its interpretation remains bounded by the reporter-only design, small animal-level evidence, and cross-study comparisons.
How CMC Shapes mRNA-LNP Translation
2026-11-05
A mechanistic editorial on how lipid chemistry, nanoparticle attributes, manufacturing comparability and orthogonal analytics shape the translation of mRNA lipid nanoparticles.
What High-Yield Rabbit Pharming Shows
2026-11-04
A targeted rabbit milk-expression study reported recombinant-protein concentrations of 15–20 g/L, but its strongest evidence is a proof-of-concept rather than a definitive demonstration of general superiority. The result supports the importance of genomic context while leaving questions about reproducibility, protein-specific performance, native milk biology and product quality unresolved.
How LNP Chemistry Shapes mRNA Translation
2026-11-04
A mechanistic editorial examines how lipid charge state, nanoparticle quality attributes, physiological stability, and manufacturing comparability influence mRNA delivery. It distinguishes what a 2026 review establishes from what remains uncertain, especially when downstream protein expression cannot identify the upstream delivery step responsible for an observed effect.
What CMC Means for mRNA-LNP Translation
2026-11-03
mRNA–lipid nanoparticle translation depends on more than delivery potency. The central challenge is connecting lipid chemistry, particle attributes, manufacturing history, physiological stability and clinical performance through a defensible chemistry, manufacturing and controls strategy.
HEPES and the Mechanism of Targeted Rabbit Pharming
2026-11-03
A 2025 rabbit study linked insertion of a fluorescent reporter into the endogenous CSN2 regulatory environment with unusually high milk expression. The result supports a locus- and promoter-focused pharming concept, but it does not establish a role for HEPES, intracellular pH modulation, or equivalent performance for therapeutic proteins.
How a CSN2 Knock-In Raised Rabbit Milk Yield
2026-11-02
A 2025 study tested whether placing a reporter gene under the endogenous rabbit CSN2 milk-protein regulatory system could overcome the variable expression associated with conventional transgenic lines. The resulting heritable line produced 15–20 g/L tdTomato in milk from two homozygous females, an encouraging but still preliminary result whose applicability to therapeutic proteins remains untested.
What the CSN2 Locus Shows in Rabbit Pharming
2026-11-02
A targeted endogenous milk-protein locus produced unusually high reporter-protein concentrations in rabbit milk, but the result remains a focused proof of concept rather than evidence of universal therapeutic-protein performance.
mRNA–LNP Translation: What CMC Evidence Shows
2026-11-01
A claim-focused synthesis of how lipid chemistry, manufacturing choices, analytical characterization, and comparability shape the translation of mRNA lipid nanoparticles, with clear boundaries around what review-level evidence can establish.
What Rabbit Pharming Results Actually Show
2026-10-31
A 2025 rabbit study provides a striking proof of concept for locus-directed expression, but its milk concentration result should not be generalized to therapeutic proteins, all transgenic lines, or HEPES-related biology. The key unresolved issues concern construct-specific performance, animal-to-animal variation, product quality, and the limits of historical comparisons.
Endogenous Milk Loci and Rabbit Pharming Yield
2026-10-30
A CRISPR/Cas9 knock-in rabbit line linked expression to the endogenous CSN2 milk-protein locus and reported tdTomato concentrations of 15–20 g/L in milk from two homozygous females. The result supports locus-directed expression as a promising strategy, but historical comparisons, a reporter cargo, and a small measured animal set limit claims about general therapeutic manufacturing.
PET Readouts of mRNA Antigen Expression
2026-10-30
A critical interpretation of a PET reporter strategy for distinguishing mRNA vaccine antigen expression from the distribution of RNA or lipid nanoparticles, with particular attention to what the evidence does—and does not—show about PEG-lipid formulation components.
A Targeted Route to High-Yield Rabbit Pharming
2026-10-29
A 2025 study tested whether placing a reporter transgene at the rabbit CSN2 milk-protein locus could overcome the variable expression and low yields associated with conventional transgenic pharming. The resulting line produced 15–20 g/L tdTomato in milk from homozygous females, an important proof of concept whose broader industrial and therapeutic relevance remains unestablished.
When Context Changes What a Cancer Result Means
2026-10-29
A pharmacological result means different things depending on whether it comes from clinical association, genetic perturbation, pathway blockade, or a downstream motility readout. In the breast-cancer study examined here, NF 340 served as a P2Y11 antagonist probe linking QPRT-associated invasiveness to purinergic signaling and myosin light-chain phosphorylation, but it did not establish therapeutic efficacy or receptor-specific causality on its own.